|
1
|
He YY, Zhang CX, Yang YY, Niu FY, Zeng Z,
Yan HH, Xu CR, Guan JL, Zhong WZ, Yang LL, et al: Prognostic
significance of genotype and number of metastatic sites in advanced
non-small-cell lung cancer. Clin Lung Cancer. 15:441–447. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yazdani S, Miki Y, Tamaki K, Ono K,
Iwabuchi E, Abe K, Suzuki T, Sato Y, Kondo T and Sasano H:
Proliferation and maturation of intratumoral blood vessels in
non-small cell lung cancer. Hum Pathol. 44:1586–1596. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Deyoung MP and Ellisen LW: P63 and p73 in
human cancer: Defining the network. Oncogene. 26:5169–5183. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yang A, Walker N, Bronson R, Kaghad M,
Oosterwegel M, Bonnin J, Vagner C, Bonnet H, Dikkes P, Sharpe A, et
al: p73-deficient mice have neurological, pheromonal and
inflammatory defects but lack spontaneous tumors. Nature.
404:99–103. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Marqués-Garcia F, Ferrandiz N,
Fernández-Alonso R, González-Cano L, Herreros-Villanueva M,
Rosa-Garrido M, Fernández-García B, Vaque JP, Marqués MM, Alonso
ME, et al: p73 plays a role in erythroid differentiation through
GATA1 induction. J Biol Chem. 284:21139–21156. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Vikhanskaya F, Bani MR, Borsotti P,
Ghilardi C, Ceruti R, Ghisleni G, Marabese M, Giavazzi R, Broggini
M and Taraboletti G: p73 overexpression increases VEGF and reduces
thrombospondin-1 production: Implications for tumor angiogenesis.
Oncogene. 20:7293–7300. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Guan M, Peng HX, Yu B and Lu Y: p73
Overexpression and angiogenesis in human colorectal carcinoma. Jpn
J Clin Oncol. 33:215–220. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Petrova V, Mancini M, Agostini M, Knight
RA, Annicchiarico-Petruzzelli M, Barlev NA, Melino G and Amelio I:
TAp73 transcriptionally represses BNIP3 expression. Cell Cycle.
14:2484–2493. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Stantic M, Sakil HA, Zirath H, Fang T,
Sanz G, Fernandez-Woodbridge A, Marin A, Susanto E, Mak TW,
Arsenian Henriksson M and Wilhelm MT: TAp73 suppresses tumor
angiogenesis through repression of proangiogenic cytokines and
HIF-1α activity. Proc Natl Acad Sci USA. 112:pp. 220–225. 2015;
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Dulloo I, Phang BH, Othman R, Tan SY,
Vijayaraghavan A, Goh LK, Martin-Lopez M, Marques MM, Li CW, Wang
de Y, et al: Hypoxia-inducible TAp73 supports tumorigenesis by
regulating the angiogenic transcriptome. Nat Cell Biol. 17:511–523.
2015. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dulloo I, Hooi PB and Sabapathy K:
Hypoxia-induced DNp73 stabilization regulates Vegf-A expression and
tumor angiogenesis similar to TAp73. Cell Cycle. 14:3533–3539.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fernandez-Alonso R, Martin-Lopez M,
Gonzalez-Cano L, Garcia S, Castrillo F, Diez-Prieto I,
Fernandez-Corona A, Lorenzo-Marcos ME, Li X, Claesson-Welsh L, et
al: p73 is required for endothelial cell differentiation, migration
and the formation of vascular networks regulating VEGF and TGFβ
signaling. Cell Death Differ. 22:1287–1299. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Salimath B, Marmé D and Finkenzeller G:
Expression of the vascular endothelial growth factor gene is
inhibited by p73. Oncogene. 19:3470–3476. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Nigro JM, Baker SJ, Preisinger AC, Jessup
JM, Hostetter R, Cleary K, Bigner SH, Davidson N, Baylin S, Devilee
P, et al: Mutations in the p53 gene occur in diverse human tumour
types. Nature. 342:705–708. 1989. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zietz C, Rössle M, Haa C, Sendelhofer A,
Hirschmann A, Stürzl M and Löhrs U: MDM-2 oncoprotein
overexpression, p53 gene mutation, and VEGF up-regulation in
angiosarcomas. Am J Pathol. 153:1425–1433. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kerbel RS: Vasohibin-1: The feedback on a
new inhibitor of angiogenesis. J Clin Invest. 114:884–886. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kern JM, Bauer K, Rychli J, Wojta J,
Ritsch A, Gastl G, Gunsilius E and Untergasser G: Alternative
splicing of vasohibin-1 generates an inhibitor of endothelial cell
proliferation, migration, and capillary tube formation.
Arterioscler Thromb Vasc Biol. 28:478–484. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yan Y, Shen Z, Ye Y, Jiang K, Zhang H,
Shen C, Mustonen H, Puolakkainen P and Wang S: A novel molecular
marker of prognosis in colorectal cancer: Vasohibin-1. Med Oncol.
31:8162014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kanomata N, Sato Y, Miyaji Y, Nagai A and
Moriya T: Vasohibin-1 is a new predictor of disease-free survival
in operated patients with renal cell carcinoma. J Clin Pathol.
66:613–619. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lu C, Han HD, Mangala LS, Ali-Fehmi R,
Newton CS, Ozbun L, Armaiz-Pena GN, Hu W, Stone RL, Munkarah A, et
al: Regulation of tumor angiogenesis by EZH2. Cancer Cell.
18:185–197. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li DJ, Zhou K, Wang SG, Shi Z and Yang Z:
Recombinant adenovirus encoding vasohibin prevents tumor
angiogenesis and inhibits tumor growth. Cancer Sci. 101:448–452.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kandoth C, McLellan MD, Vandin F, Ye K,
Niu B, Lu C, Xie M, Zhang Q, McMichael JF, Wyczalkowski MA, et al:
Mutational landscape and significance across 12 major cancer types.
Nature. 502:333–339. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Oren M and Rotter V: Mutant p53
gain-of-function in cancer. Cold Spring Harb Perspect Biol.
2:a0011072010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Melino G, Laurenzi VD and Vousden KH: p73:
Friend or foe in tumorigenesis. Nat Rev Cancer. 2:605–615. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Levrero M, Laurenzi DV, Costanzo A, Gong
J, Wang JY and Melino G: The p53/p63/p73 family of transcription
factors: Overlapping and distinct functions. J Cell Sci.
113:1661–1670. 2000.PubMed/NCBI
|
|
26
|
Amelio I, Inoue S, Markert EK, Levine AJ,
Knight RA, Mak TW and Melino G: TAp73 opposes tumor angiogenesis by
promoting hypoxia-inducible factor 1α degradation. Proc Natl Acad
Sci USA. 112:pp. 226–231. 2015; View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yoshinaga K, Ito K, Moriya T, Nagase S,
Takano T, Niikura H, Sasano H, Yaegashi N and Sato Y: Roles of
intrinsic angiogenesis inhibitor, vasohibin, in cervical
carcinomas. Cancer Sci. 102:446–451. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tamaki K, Sasano H, Maruo Y, Takahashi Y,
Miyashita M, Moriya T, Sato Y, Hirakawa H, Tamaki N, Watanabe M, et
al: Vasohibin-1 as a potential predictor of aggressive behavior of
ductal carcinoma in situ of the breast. Cancer Sci. 101:1051–1058.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang Q, Tian X, Zhang C and Wang Q:
Upregulation of vasohibin-1 expression with angiogenesis and poor
prognosis of hepatocellular carcinoma after curative surgery. Med
Oncol. 29:2727–2736. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Takahashi Y, Koyanagi T, Suzuki Y, Saga Y,
Kanomata N, Moriya T, Suzuki M and Sato Y: Vasohibin-2 expressed in
human serous ovarian adenocarcinoma accelerates tumor growth by
promoting angiogenesis. Mol Cancer Res. 10:1135–1146. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhang T, Yu TT, Zhang DM, Hou XM, Liu XJ,
Zhao D and Shan L: Vasohibin-1 expression detected by
immunohistochemistry correlates with prognosis in non-small cell
lung cancer. Med Oncol. 31:9632014. View Article : Google Scholar : PubMed/NCBI
|
